A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

Antonio Jimeno, Julie E. Bauman, Charles Weissman, Douglas Adkins, Ian Schnadig, Patrice Beauregard, Daniel W. Bowles, Alexander Spira, Benjamin Levy, Nagashree Seetharamu, Diana Hausman, Luke Walker, Charles M. Rudin, Keisuke Shirai

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences